These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21084750)

  • 1. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.
    Ha SP; Klemen ND; Kinnebrew GH; Brandmaier AG; Marsh J; Hangoc G; Palmer DC; Restifo NP; Cornetta K; Broxmeyer HE; Touloukian CE
    J Clin Invest; 2010 Dec; 120(12):4273-88. PubMed ID: 21084750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visualization of the human CD4⁺ T-cell response in humanized HLA-DR4-expressing NOD/Shi-scid/γc(null) (NOG) mice by retrogenic expression of the human TCR gene.
    Takahashi T; Katano I; Ito R; Ito M
    Biochem Biophys Res Commun; 2015 Jan; 456(1):219-24. PubMed ID: 25462565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.
    Mehrotra S; Al-Khami AA; Klarquist J; Husain S; Naga O; Eby JM; Murali AK; Lyons GE; Li M; Spivey ND; Norell H; Martins da Palma T; Onicescu G; Diaz-Montero CM; Garrett-Mayer E; Cole DJ; Le Poole IC; Nishimura MI
    J Immunol; 2012 Aug; 189(4):1627-38. PubMed ID: 22798675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.
    Ali R; Babad J; Follenzi A; Gebe JA; Brehm MA; Nepom GT; Shultz LD; Greiner DL; DiLorenzo TP
    Immunology; 2016 Aug; 148(4):339-51. PubMed ID: 27124592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
    Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
    J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
    Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
    J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.
    Gregg RK; Nichols L; Chen Y; Lu B; Engelhard VH
    J Immunol; 2010 Feb; 184(4):1909-17. PubMed ID: 20083666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
    Gattinoni L; Ranganathan A; Surman DR; Palmer DC; Antony PA; Theoret MR; Heimann DM; Rosenberg SA; Restifo NP
    Blood; 2006 Dec; 108(12):3818-23. PubMed ID: 16882704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.
    Rausch MP; Irvine KR; Antony PA; Restifo NP; Cresswell P; Hastings KT
    J Immunol; 2010 Sep; 185(5):2828-35. PubMed ID: 20668223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.
    Giannoni F; Hardee CL; Wherley J; Gschweng E; Senadheera S; Kaufman ML; Chan R; Bahner I; Gersuk V; Wang X; Gjertson D; Baltimore D; Witte ON; Economou JS; Ribas A; Kohn DB
    Mol Ther; 2013 May; 21(5):1044-54. PubMed ID: 23380815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.
    Yang L; Baltimore D
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4518-23. PubMed ID: 15758071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
    Plewa N; Poncette L; Blankenstein T
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
    Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
    Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
    Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
    Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
    Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
    Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
    Hu Z; Xia J; Fan W; Wargo J; Yang YG
    Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions.
    Lambe T; Leung JC; Bouriez-Jones T; Silver K; Makinen K; Crockford TL; Ferry H; Forrester JV; Cornall RJ
    J Immunol; 2006 Sep; 177(5):3055-62. PubMed ID: 16920942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized transgenic mice expressing HLA DR4-DQ3 haplotype: reconstitution of phenotype and HLA-restricted T-cell responses.
    Chen Z; de Kauwe AL; Keech C; Wijburg O; Simpfendorfer K; Alexander WS; McCluskey J
    Tissue Antigens; 2006 Sep; 68(3):210-9. PubMed ID: 16948641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting rare populations of murine antigen-specific T lymphocytes by retroviral transduction for potential application in gene therapy for autoimmune disease.
    Costa GL; Benson JM; Seroogy CM; Achacoso P; Fathman CG; Nolan GP
    J Immunol; 2000 Apr; 164(7):3581-90. PubMed ID: 10725713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.